Skip to main
  1. Stocks
  2. Faeth Therapeutics Inc
  3. Forecast
FTH

FTH Stock Forecast & Price Target

FTH Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Faeth Therapeutics is attractive because PIKTOR’s dual PI3Kα and mTORC1/2 blockade is supported by strong mechanistic and preclinical data showing deeper PAM-pathway suppression than single-node inhibitors, with an all-oral design that avoids the IV burden of comparators. The investment case is further strengthened by early clinical signals: the January 2026 data showed about 14% all-grade stomatitis and 0% grade 3+ stomatitis, while the company ended 3Q26 with $174.8M in cash, providing runway into the YE26 PIK-201 readout. That upcoming ~40-patient endometrial dataset is viewed as a key catalyst because an ORR above 30% with tolerable safety could validate the program in a large, high-unmet-need market and de-risk breast-cancer expansion.

Bears say

Faeth Therapeutics is a clinical-stage biotech with high execution risk because its lead PIKTOR program must prove both meaningful efficacy and acceptable safety in breast and endometrial cancer, yet the cited evidence points to a narrow therapeutic window, trial delays, and the possibility of disappointing FTH-PIK-101 phase 1b/2 results versus Street expectations. The company also faces a crowded and improving competitive backdrop, with strong gedatolisib launch dynamics and other PI3Kα or alternate-modality programs showing clinical benefit, while single-node pathway inhibition has repeatedly been undermined by rapid adaptive resistance and parallel-pathway mutations. Given the added financing burden if clinical or commercial progress falters, and the risk that PIKTOR may fail to gain share or launch successfully, the fundamental outlook remains negative.

FTH has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Faeth Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

FTH Analyst Forecast & Price Prediction

Get the latest FTH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in FTH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Faeth Therapeutics Inc (FTH) Forecast

Analysts have given FTH a Strong Buy based on their latest research and market trends.

According to 11 analysts, FTH has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Faeth Therapeutics Inc (FTH)


FTH Analyst Forecast & Price Prediction

Get the latest FTH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in FTH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover FTH stock data and trends